The influence of familial and hereditary factors on the prognosis of breast cancer

Chappuis, P.; Rosenblatt, Jacalyn; Foulkes, William D.

doi:10.1023/a:1008301314812

Cited by 52 publications

(42 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This yielded five reviews (58)(59)(60)(61)(62). None of the reviews included pooled analyses of study outcomes, and thus, the included original articles were retrieved and examined.…”

Section: A2 Literature Searches Regarding Input Values For the Modelmentioning

confidence: 99%

Breast Cancer Screening, Outside the Population-Screening Program, of Women from Breast Cancer Families without Proven BRCA1/BRCA2 Mutations: a Simulation Study

Jacobi

Nagelkerke²,

Houwelingen³

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Purpose: We assessed the cost-effectiveness of mammography screening for women under the age of 50, from breast cancer families without proven BRCA1/BRCA2 mutations, because current criteria for screening healthy women from breast cancer families are not evidence-based. Methods: We did simulation studies with mathematical models on the cost-effectiveness of mammography screening of women under the age of 50 with breast cancer family histories. Breast cancer screening was simulated with varying screening intervals (6, 12, 18, and 24 months) and screening cohorts (starting at ages 30, 35, 40, and 45, and continuing to age 50). Incremental costs of screening were compared with those of women ages 50 to 52 years, the youngest age group currently routinely screened in the nationwide screening program of the Netherlands, to determine cost-effectiveness. Sensitivity analyses were done to explore the effects of model assumptions. The cost-effectiveness of breast cancer screening for women over the age of 50 was not debated. Results: The most effective screening interval was found to be 12 months, which, however, seems only to be costeffective in a small group of women under the age of 50 with at least two affected relatives, including at least one affected in the first degree diagnosed under the age of 50. Significantly, early breast cancer screening never seemed to be costeffective in women with only one affected first-degree or second-degree relative. Conclusion: Annual breast cancer screening with mammography for women under the age of 50 seems to be costeffective in women with strong family histories of breast cancer, even when no BRCA1/BRCA2 mutation was found in affected family members. (Cancer Epidemiol Biomarkers Prev 2006;15(3):429 -36)

show abstract

“…This yielded five reviews (58)(59)(60)(61)(62). None of the reviews included pooled analyses of study outcomes, and thus, the included original articles were retrieved and examined.…”

Section: A2 Literature Searches Regarding Input Values For the Modelmentioning

confidence: 99%

Breast Cancer Screening, Outside the Population-Screening Program, of Women from Breast Cancer Families without Proven BRCA1/BRCA2 Mutations: a Simulation Study

Jacobi

Nagelkerke²,

Houwelingen³

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Therefore, a large proportion of the familial clustering of breast and ovarian cancer remains unexplained. Particular clinicopathological characteristics and differences in outcome have been reported for cases of breast cancer developing in familial clusters compared to sporadic cases [11].…”

Section: Introductionmentioning

confidence: 99%

Set-up of a population-based familial breast cancer registry in Geneva Switzerland: Validation of first results

Verkooijen¹,

Fioretta²,

Chappuis³

et al. 2004

European Journal of Cancer Supplements

View full text Add to dashboard Cite

Background: This article evaluates the accuracy of family history of breast and ovarian cancer among firstdegree relatives of breast cancer patients, retrospectively collected during the setting up of a population-based family breast cancer registry. Patients and methods: Family histories of cancer for all women with breast cancer recorded at the Geneva Cancer Registry from 1990 to 1999 were retrospectively extracted from medical files. The accuracy of these family histories was validated among Swiss women born in Geneva: all 119 with a family history of breast (n = 110) or ovarian (n = 9) cancer and a representative sample of 100 women with no family history of breast or ovarian cancer. We identified the first-degree relatives of these women with information from the Cantonal Population Office. All first-degree relatives, resident in Geneva from 1970 to 1999, were linked to the cancer registry database for breast and ovarian cancer occurrence. Sensitivity, specificity and level of overall agreement (κ) were calculated. Results: Among 310 first-degree relatives identified, 61 had breast cancer and six had ovarian cancer recorded at the Geneva Cancer Registry. The sensitivity, specificity and κ of the reported family histories of breast cancer were 98%, 97% and 0.97, respectively. For ovarian cancer, the sensitivity, specificity and κ were 67%, 99%, and 0.66, respectively. Conclusions: This study indicates that retrospectively obtained family histories are very accurate for breast cancer. For ovarian cancer, family histories are less precise and may need additional verification.

show abstract

“…Conflicting data exist on the impact of a family history of breast or ovarian cancer on the outcome of breast cancer (Ruder et al, 1988;Chappuis et al, 1999;Russo et al, 2002). Some studies have shown improved survival rates among breast cancer patients with affected relatives compared to those without a family history (Malone et al, 1996;Mohammed et al, 1998), some reported poorer survival rates (Slattery et al, 1993;Gonzalez-Angulo et al, 2005), and others did not find any survival difference between patients with or without a family history (Greenberg et al, 1985;Kinoshita et al, 2004).…”

mentioning

confidence: 99%

Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study

et al. 2005

View full text Add to dashboard Cite

This population-based study evaluates the impact of a strong family history of breast cancer on management and survival of women with early-onset disease. We identified all breast cancer patients p50 years, recorded between 1990 and 2001 at the Geneva familial breast cancer registry. We compared patients at high familial risk and low familial risk in terms of tumour characteristics, method of detection, treatment, survival and breast cancer mortality risk. Compared to patients at low familial risk (n ¼ 575), those at high familial risk (n ¼ 58) received significantly more often systemic therapy, especially for node-negative or receptor-positive disease. Five-year disease-specific survival rates of patients at high vs low familial risk were 86 and 90%, respectively. After adjustment, there was no difference in breast cancer mortality in general. A strong family history nonsignificantly increased breast cancer mortality in patients p40 years (adjusted hazard ratio (HR) 4.0, 95% CI 0.8 -19.7) and in patients treated without chemotherapy (adjusted HR 2.7, 95% CI 0.6 -12.5). A strong family history of breast cancer is associated with an increased use of systemic therapy in early-onset patients. Although a strong family history does not seem to affect survival in general, it may impair survival of very young patients and patients treated without adjuvant chemotherapy. Owing to the limited number of patients in this study, these results should be used only to generate hypotheses.

show abstract

The influence of familial and hereditary factors on the prognosis of breast cancer

Cited by 52 publications

References 49 publications

Breast Cancer Screening, Outside the Population-Screening Program, of Women from Breast Cancer Families without Proven BRCA1/BRCA2 Mutations: a Simulation Study

Breast Cancer Screening, Outside the Population-Screening Program, of Women from Breast Cancer Families without Proven BRCA1/BRCA2 Mutations: a Simulation Study

Set-up of a population-based familial breast cancer registry in Geneva Switzerland: Validation of first results

Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study

Contact Info

Product

Resources

About